Beijing Mario Biotech

Beijing Mario Biotech is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of next-generation chimeric antigen receptor T-cell (CAR-T) therapies. The company's lead candidate, MAR-001, is a CD19-targeted CAR-T therapy being evaluated for B-cell malignancies, including lymphoma and leukemia. Additionally, the company is advancing a pipeline of personalized CAR-T therapies targeting solid tumors, specifically glioblastoma, with targets such as EGFRvIII and HER2. Beijing Mario Biotech leverages its proprietary cell therapy platform to improve the safety and efficacy of CAR-T treatments, aiming to address unmet needs in oncology.